[The treatment of Paget's disease of bone with second-generation bisphosphonates via intravenous infusion].
We compared the biochemical effects and safety of pamidronate (30 mg a day for 3 consecutive days) versus clodronate (300 mg a day for 3 consecutive days) via intravenous infusion in 14 patients with Paget's disease of bone (PDB). Both drugs induced a decrease in serum alkaline phosphatase levels as well as the elimination of hydroxyproline from urine, an effect most marked in the group treated with pamidronate. The response was maintained for 6 months after the infusion in the majority of the patients. No relevant side effects were found, except post-infusion febricula and in one patient, self-limiting thrombopenia 6 months after the infusion. We conclude that the intravenous infusion of either of the two drugs may constitute a safe and effective alternative for treatment of PDB with marked biochemical activity or resistant to conventional therapy.
Arboleya
L
L
Unidad de Reumatología, Hospital Río Carrión, Palencia.
Sánchez
J
J
Iglesias
G
G
Arranz
J L
JL
D000368:Aged; D000469:Alkaline Phosphatase / Q000097:blood / Q000187:drug effects; D004164:Diphosphonates / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000187:drug effects / Q000652:urine; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000188:drug therapy* / Q000453:epidemiology / Q000378:metabolism; D011446:Prospective Studies; D013997:Time Factors
D004164:Diphosphonates; D000469:Alkaline Phosphatase; D006909:Hydroxyproline
Tratamiento de la enfermedad ósea de Paget con bifosfonatos de segunda generación en infusión intravenosa.